Published in Cell Res on August 27, 2013
CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol (2014) 9.18
Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells. Nat Biotechnol (2014) 5.07
Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing. Nat Biotechnol (2014) 4.41
Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. Nat Biotechnol (2015) 3.56
The rise of regulatory RNA. Nat Rev Genet (2014) 3.02
High-throughput functional genomics using CRISPR-Cas9. Nat Rev Genet (2015) 2.35
A protein-tagging system for signal amplification in gene expression and fluorescence imaging. Cell (2014) 2.27
Functional annotation of native enhancers with a Cas9-histone demethylase fusion. Nat Methods (2015) 2.22
Multiplexed and programmable regulation of gene networks with an integrated RNA and CRISPR/Cas toolkit in human cells. Mol Cell (2014) 2.02
Multiplex genome engineering in human cells using all-in-one CRISPR/Cas9 vector system. Sci Rep (2014) 1.83
A mouse geneticist's practical guide to CRISPR applications. Genetics (2014) 1.81
Considerations when investigating lncRNA function in vivo. Elife (2014) 1.61
A co-CRISPR strategy for efficient genome editing in Caenorhabditis elegans. Genetics (2014) 1.60
CRISPR-based technologies: prokaryotic defense weapons repurposed. Trends Genet (2014) 1.60
Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector. Nucleic Acids Res (2014) 1.59
Cas9 effector-mediated regulation of transcription and differentiation in human pluripotent stem cells. Development (2014) 1.59
sgRNAcas9: a software package for designing CRISPR sgRNA and evaluating potential off-target cleavage sites. PLoS One (2014) 1.54
A light-inducible CRISPR-Cas9 system for control of endogenous gene activation. Nat Chem Biol (2015) 1.48
A CRISPR view of development. Genes Dev (2014) 1.41
SWITCH: a dynamic CRISPR tool for genome engineering and metabolic pathway control for cell factory construction in Saccharomyces cerevisiae. Microb Cell Fact (2017) 1.40
Making designer mutants in model organisms. Development (2014) 1.38
Direct activation of human and mouse Oct4 genes using engineered TALE and Cas9 transcription factors. Nucleic Acids Res (2014) 1.34
Applications of the CRISPR-Cas9 system in cancer biology. Nat Rev Cancer (2015) 1.32
COSMID: A Web-based Tool for Identifying and Validating CRISPR/Cas Off-target Sites. Mol Ther Nucleic Acids (2014) 1.27
Comparison of TALE designer transcription factors and the CRISPR/dCas9 in regulation of gene expression by targeting enhancers. Nucleic Acids Res (2014) 1.25
Editing the epigenome: technologies for programmable transcription and epigenetic modulation. Nat Methods (2016) 1.24
Target specificity of the CRISPR-Cas9 system. Quant Biol (2014) 1.23
Efficient chromosomal gene modification with CRISPR/cas9 and PCR-based homologous recombination donors in cultured Drosophila cells. Nucleic Acids Res (2014) 1.23
Off-target Effects in CRISPR/Cas9-mediated Genome Engineering. Mol Ther Nucleic Acids (2015) 1.23
Beyond editing: repurposing CRISPR-Cas9 for precision genome regulation and interrogation. Nat Rev Mol Cell Biol (2015) 1.20
Visualization of specific DNA sequences in living mouse embryonic stem cells with a programmable fluorescent CRISPR/Cas system. Nucleus (2014) 1.20
Inhibition of pluripotency networks by the Rb tumor suppressor restricts reprogramming and tumorigenesis. Cell Stem Cell (2014) 1.11
Origins, genetic landscape, and emerging therapies of small cell lung cancer. Genes Dev (2015) 1.11
Advances in CRISPR-Cas9 genome engineering: lessons learned from RNA interference. Nucleic Acids Res (2015) 1.10
Choosing the Right Tool for the Job: RNAi, TALEN, or CRISPR. Mol Cell (2015) 1.09
A CRISPR/Cas9-based system for reprogramming cell lineage specification. Stem Cell Reports (2014) 1.09
CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes. Cell (2016) 1.08
Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting. Cancer Discov (2016) 1.08
Exploiting CRISPR/Cas systems for biotechnology. Bioessays (2014) 1.06
Epigenetics and the regulation of stress vulnerability and resilience. Neuroscience (2013) 1.06
Development of an intein-mediated split-Cas9 system for gene therapy. Nucleic Acids Res (2015) 1.03
A CRISPR/Cas9 Toolbox for Multiplexed Plant Genome Editing and Transcriptional Regulation. Plant Physiol (2015) 1.03
Mouse genome engineering via CRISPR-Cas9 for study of immune function. Immunity (2015) 1.02
Spell Checking Nature: Versatility of CRISPR/Cas9 for Developing Treatments for Inherited Disorders. Am J Hum Genet (2015) 1.00
Cas9-chromatin binding information enables more accurate CRISPR off-target prediction. Nucleic Acids Res (2015) 1.00
Efficient programmable gene silencing by Cascade. Nucleic Acids Res (2014) 1.00
Making sense of GWAS: using epigenomics and genome engineering to understand the functional relevance of SNPs in non-coding regions of the human genome. Epigenetics Chromatin (2015) 0.99
Potent and Targeted Activation of Latent HIV-1 Using the CRISPR/dCas9 Activator Complex. Mol Ther (2015) 0.98
CRISPR/gRNA-directed synergistic activation mediator (SAM) induces specific, persistent and robust reactivation of the HIV-1 latent reservoirs. Sci Rep (2015) 0.98
Comparison of Cas9 activators in multiple species. Nat Methods (2016) 0.96
Resources for the design of CRISPR gene editing experiments. Genome Biol (2015) 0.95
CRISPR-Cas9 Genome Editing in Drosophila. Curr Protoc Mol Biol (2015) 0.95
Regulation of endogenous human gene expression by ligand-inducible TALE transcription factors. ACS Synth Biol (2013) 0.94
Conditionally Stabilized dCas9 Activator for Controlling Gene Expression in Human Cell Reprogramming and Differentiation. Stem Cell Reports (2015) 0.94
Engineering synthetic TALE and CRISPR/Cas9 transcription factors for regulating gene expression. Methods (2014) 0.93
Genome-wide specificity of DNA binding, gene regulation, and chromatin remodeling by TALE- and CRISPR/Cas9-based transcriptional activators. Genome Res (2015) 0.92
Activating human genes with zinc finger proteins, transcription activator-like effectors and CRISPR/Cas9 for gene therapy and regenerative medicine. Expert Opin Ther Targets (2014) 0.90
Enabling functional genomics with genome engineering. Genome Res (2015) 0.90
In Vivo Transcriptional Activation Using CRISPR/Cas9 in Drosophila. Genetics (2015) 0.90
Efficient Generation of Myostatin Mutations in Pigs Using the CRISPR/Cas9 System. Sci Rep (2015) 0.90
Casilio: a versatile CRISPR-Cas9-Pumilio hybrid for gene regulation and genomic labeling. Cell Res (2016) 0.89
Detailed phenotypic and molecular analyses of genetically modified mice generated by CRISPR-Cas9-mediated editing. PLoS One (2015) 0.89
CRISPR-Cas systems: new players in gene regulation and bacterial physiology. Front Cell Infect Microbiol (2014) 0.89
Precision cancer mouse models through genome editing with CRISPR-Cas9. Genome Med (2015) 0.89
Cornerstones of CRISPR-Cas in drug discovery and therapy. Nat Rev Drug Discov (2016) 0.88
Targeted HIV-1 Latency Reversal Using CRISPR/Cas9-Derived Transcriptional Activator Systems. PLoS One (2016) 0.87
Excision of Expanded GAA Repeats Alleviates the Molecular Phenotype of Friedreich's Ataxia. Mol Ther (2015) 0.87
The New State of the Art: Cas9 for Gene Activation and Repression. Mol Cell Biol (2015) 0.87
Modeling Disease In Vivo With CRISPR/Cas9. Trends Mol Med (2015) 0.87
Targeting CDK11 in osteosarcoma cells using the CRISPR-Cas9 system. J Orthop Res (2014) 0.86
Functional genetics for all: engineered nucleases, CRISPR and the gene editing revolution. Evodevo (2014) 0.86
Tracking and transforming neocortical progenitors by CRISPR/Cas9 gene targeting and piggyBac transposase lineage labeling. Development (2015) 0.86
Inheritable Silencing of Endogenous Genes by Hit-and-Run Targeted Epigenetic Editing. Cell (2016) 0.86
Targeted Epigenetic Remodeling of Endogenous Loci by CRISPR/Cas9-Based Transcriptional Activators Directly Converts Fibroblasts to Neuronal Cells. Cell Stem Cell (2016) 0.85
Histone H3 globular domain acetylation identifies a new class of enhancers. Nat Genet (2016) 0.84
Applications of CRISPR-Cas9 mediated genome engineering. Mil Med Res (2015) 0.84
Electroporation Knows No Boundaries: The Use of Electrostimulation for siRNA Delivery in Cells and Tissues. J Biomol Screen (2015) 0.84
CRISPR-Cas9-mediated genome editing and guide RNA design. Mamm Genome (2015) 0.84
CRISPR/dCas9-mediated Transcriptional Inhibition Ameliorates the Epigenetic Dysregulation at D4Z4 and Represses DUX4-fl in FSH Muscular Dystrophy. Mol Ther (2015) 0.84
Regulation of transcriptionally active genes via the catalytically inactive Cas9 in C. elegans and D. rerio. Cell Res (2015) 0.83
Chromatin remodeling and bivalent histone modifications in embryonic stem cells. EMBO Rep (2015) 0.83
The therapeutic application of CRISPR/Cas9 technologies for HIV. Expert Opin Biol Ther (2015) 0.83
A new age in functional genomics using CRISPR/Cas9 in arrayed library screening. Front Genet (2015) 0.83
Precision genetic modifications: a new era in molecular biology and crop improvement. Planta (2014) 0.83
Advanced In vivo Use of CRISPR/Cas9 and Anti-sense DNA Inhibition for Gene Manipulation in the Brain. Front Genet (2016) 0.82
Future of breeding by genome editing is in the hands of regulators. GM Crops Food (2015) 0.81
Genome-editing tools for stem cell biology. Cell Death Dis (2015) 0.81
Applications of Engineered DNA-Binding Molecules Such as TAL Proteins and the CRISPR/Cas System in Biology Research. Int J Mol Sci (2015) 0.81
Specific Reactivation of Latent HIV-1 by dCas9-SunTag-VP64-mediated Guide RNA Targeting the HIV-1 Promoter. Mol Ther (2016) 0.81
Writing of H3K4Me3 overcomes epigenetic silencing in a sustained but context-dependent manner. Nat Commun (2016) 0.80
Efficient Production of Gene-Modified Mice using Staphylococcus aureus Cas9. Sci Rep (2016) 0.80
Epigenetic mechanisms underlying the pathogenesis of neurogenetic diseases. Neurotherapeutics (2014) 0.80
Combining CRISPR/Cas9 and rAAV Templates for Efficient Gene Editing. Nucleic Acid Ther (2015) 0.79
Upregulating endogenous genes by an RNA-programmable artificial transactivator. Nucleic Acids Res (2015) 0.79
Strategies for precision modulation of gene expression by epigenome editing: an overview. Epigenetics Chromatin (2015) 0.79
CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer. Cancer Gene Ther (2015) 0.79
Correction of Monogenic and Common Retinal Disorders with Gene Therapy. Genes (Basel) (2017) 0.79
Psip1/p52 regulates posterior Hoxa genes through activation of lncRNA Hottip. PLoS Genet (2017) 0.78
Spatial genome organization and cognition. Nat Rev Neurosci (2016) 0.78
Suppression of oxidative phosphorylation in mouse embryonic fibroblast cells deficient in apurinic/apyrimidinic endonuclease. DNA Repair (Amst) (2015) 0.78
Multiplex genome engineering using CRISPR/Cas systems. Science (2013) 55.53
RNA-guided human genome engineering via Cas9. Science (2013) 48.29
A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science (2012) 48.17
affy--analysis of Affymetrix GeneChip data at the probe level. Bioinformatics (2004) 32.08
One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell (2013) 24.00
Breaking the code of DNA binding specificity of TAL-type III effectors. Science (2009) 22.33
Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat Biotechnol (2013) 21.32
A simple cipher governs DNA recognition by TAL effectors. Science (2009) 19.99
DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol (2013) 19.99
RNA-guided genetic silencing systems in bacteria and archaea. Nature (2012) 17.12
RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nat Biotechnol (2013) 15.51
RNA-programmed genome editing in human cells. Elife (2013) 14.82
Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell (2013) 13.43
Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. Nat Biotechnol (2011) 12.86
CRISPR-Cas systems in bacteria and archaea: versatile small RNAs for adaptive defense and regulation. Annu Rev Genet (2011) 9.88
CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell (2013) 9.55
Nanog is the gateway to the pluripotent ground state. Cell (2009) 7.27
Toward controlling gene expression at will: specific regulation of the erbB-2/HER-2 promoter by using polydactyl zinc finger proteins constructed from modular building blocks. Proc Natl Acad Sci U S A (1998) 5.46
Transcription factors: from enhancer binding to developmental control. Nat Rev Genet (2012) 5.00
Positive and negative regulation of endogenous genes by designed transcription factors. Proc Natl Acad Sci U S A (2000) 3.92
Synergistic and tunable human gene activation by combinations of synthetic transcription factors. Nat Methods (2013) 3.26
Robust, synergistic regulation of human gene expression using TALE activators. Nat Methods (2013) 2.89
Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med (2010) 2.50
Designing transcription factor architectures for drug discovery. Mol Pharmacol (2004) 2.44
Zinc-finger-based artificial transcription factors and their applications. Adv Drug Deliv Rev (2009) 1.25
Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature (2007) 65.18
A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell (2006) 48.80
Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature (2009) 35.48
Core transcriptional regulatory circuitry in human embryonic stem cells. Cell (2005) 34.93
Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature (2008) 30.29
In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature (2007) 28.24
Control of developmental regulators by Polycomb in human embryonic stem cells. Cell (2006) 28.21
Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature (2006) 25.90
One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell (2013) 24.00
A chromatin landmark and transcription initiation at most promoters in human cells. Cell (2007) 23.41
Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution. Cell Stem Cell (2007) 21.58
Dissecting direct reprogramming through integrative genomic analysis. Nature (2008) 16.47
Connecting microRNA genes to the core transcriptional regulatory circuitry of embryonic stem cells. Cell (2008) 16.38
Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc Natl Acad Sci U S A (2010) 15.13
Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell (2009) 13.02
Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science (2007) 12.41
Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat Biotechnol (2009) 12.40
Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell (2008) 12.29
Sequential expression of pluripotency markers during direct reprogramming of mouse somatic cells. Cell Stem Cell (2008) 12.29
Genetic engineering of human pluripotent cells using TALE nucleases. Nat Biotechnol (2011) 11.76
Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell (2011) 11.44
Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency. Cell (2008) 10.68
Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell (2005) 9.84
A protein interaction network for pluripotency of embryonic stem cells. Nature (2006) 9.63
Cre-lox-regulated conditional RNA interference from transgenes. Proc Natl Acad Sci U S A (2004) 9.33
DGCR8 is essential for microRNA biogenesis and silencing of embryonic stem cell self-renewal. Nat Genet (2007) 9.25
HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell (2003) 9.12
Direct reprogramming of genetically unmodified fibroblasts into pluripotent stem cells. Nat Biotechnol (2007) 9.04
Induction of tumors in mice by genomic hypomethylation. Science (2003) 8.86
Direct cell reprogramming is a stochastic process amenable to acceleration. Nature (2009) 8.71
Reduced representation bisulfite sequencing for comparative high-resolution DNA methylation analysis. Nucleic Acids Res (2005) 8.69
Promotion of reprogramming to ground state pluripotency by signal inhibition. PLoS Biol (2008) 8.55
Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. Science (2003) 8.48
c-Myc is dispensable for direct reprogramming of mouse fibroblasts. Cell Stem Cell (2007) 8.46
YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol (2007) 8.11
One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering. Cell (2013) 7.99
A drug-inducible transgenic system for direct reprogramming of multiple somatic cell types. Nat Biotechnol (2008) 7.91
Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci U S A (2008) 7.52
Nanog is the gateway to the pluripotent ground state. Cell (2009) 7.27
Single-cell expression analyses during cellular reprogramming reveal an early stochastic and a late hierarchic phase. Cell (2012) 7.17
HDAC2 negatively regulates memory formation and synaptic plasticity. Nature (2009) 6.96
The role of Tet3 DNA dioxygenase in epigenetic reprogramming by oocytes. Nature (2011) 6.73
Efficient method to generate single-copy transgenic mice by site-specific integration in embryonic stem cells. Genesis (2006) 6.64
Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell (2011) 6.56
Chromosomal instability and tumors promoted by DNA hypomethylation. Science (2003) 6.02
Chromosomal silencing and localization are mediated by different domains of Xist RNA. Nat Genet (2002) 5.51
Promoter CpG methylation contributes to ES cell gene regulation in parallel with Oct4/Nanog, PcG complex, and histone H3 K4/K27 trimethylation. Cell Stem Cell (2008) 5.40
Oct4 expression is not required for mouse somatic stem cell self-renewal. Cell Stem Cell (2007) 5.29
Pluripotency and cellular reprogramming: facts, hypotheses, unresolved issues. Cell (2010) 5.13
Human embryonic stem cells with biological and epigenetic characteristics similar to those of mouse ESCs. Proc Natl Acad Sci U S A (2010) 5.00
The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression. Neuron (2006) 4.74
Reprogramming of neural progenitor cells into induced pluripotent stem cells in the absence of exogenous Sox2 expression. Stem Cells (2008) 4.67
Chromatin structure and gene expression programs of human embryonic and induced pluripotent stem cells. Cell Stem Cell (2010) 4.59
Correction of a genetic defect by nuclear transplantation and combined cell and gene therapy. Cell (2002) 4.56
Tet1 is dispensable for maintaining pluripotency and its loss is compatible with embryonic and postnatal development. Cell Stem Cell (2011) 4.52
Reduced cortical activity due to a shift in the balance between excitation and inhibition in a mouse model of Rett syndrome. Proc Natl Acad Sci U S A (2005) 4.52
Reprogramming of murine and human somatic cells using a single polycistronic vector. Proc Natl Acad Sci U S A (2008) 4.48
Wnt signaling promotes reprogramming of somatic cells to pluripotency. Cell Stem Cell (2008) 4.43
Analysis of histone 2B-GFP retention reveals slowly cycling hematopoietic stem cells. Nat Biotechnol (2008) 4.41
Derivation of pre-X inactivation human embryonic stem cells under physiological oxygen concentrations. Cell (2010) 4.32
Monoclonal mice generated by nuclear transfer from mature B and T donor cells. Nature (2002) 4.16
Functional genomics, proteomics, and regulatory DNA analysis in isogenic settings using zinc finger nuclease-driven transgenesis into a safe harbor locus in the human genome. Genome Res (2010) 3.94
Metastable pluripotent states in NOD-mouse-derived ESCs. Cell Stem Cell (2009) 3.92
H2AZ is enriched at polycomb complex target genes in ES cells and is necessary for lineage commitment. Cell (2008) 3.90
DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction. Nat Genet (2009) 3.73
Nuclear reprogramming and pluripotency. Nature (2006) 3.68
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood (2006) 3.48
Technical challenges in using human induced pluripotent stem cells to model disease. Cell Stem Cell (2009) 3.42
Stat3 activation is limiting for reprogramming to ground state pluripotency. Cell Stem Cell (2010) 3.42
Combined deficiency of Tet1 and Tet2 causes epigenetic abnormalities but is compatible with postnatal development. Dev Cell (2013) 3.31
Reprogramming factor stoichiometry influences the epigenetic state and biological properties of induced pluripotent stem cells. Cell Stem Cell (2011) 3.31
DNA methylation in the human cerebral cortex is dynamically regulated throughout the life span and involves differentiated neurons. PLoS One (2007) 3.30
Transcriptional profiling of a mouse model for Rett syndrome reveals subtle transcriptional changes in the brain. Proc Natl Acad Sci U S A (2002) 3.29
Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice. Proc Natl Acad Sci U S A (2009) 3.23
Incomplete reactivation of Oct4-related genes in mouse embryos cloned from somatic nuclei. Development (2003) 3.22
Combinatorial development of biomaterials for clonal growth of human pluripotent stem cells. Nat Mater (2010) 3.11
Reprogramming of human peripheral blood cells to induced pluripotent stem cells. Cell Stem Cell (2010) 3.08
Reprogramming efficiency following somatic cell nuclear transfer is influenced by the differentiation and methylation state of the donor nucleus. Stem Cells (2006) 3.07
Broader implications of defining standards for the pluripotency of iPSCs. Cell Stem Cell (2009) 3.03
Maternal and zygotic Dnmt1 are necessary and sufficient for the maintenance of DNA methylation imprints during preimplantation development. Genes Dev (2008) 2.99
Uracil DNA glycosylase activity is dispensable for immunoglobulin class switch. Science (2004) 2.93
Mice cloned from olfactory sensory neurons. Nature (2004) 2.90
Expression of MeCP2 in postmitotic neurons rescues Rett syndrome in mice. Proc Natl Acad Sci U S A (2004) 2.87
Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats. Proc Natl Acad Sci U S A (2010) 2.85
Functional genomics of genes with small open reading frames (sORFs) in S. cerevisiae. Genome Res (2006) 2.81
Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of Klf4. Proc Natl Acad Sci U S A (2009) 2.80
Rapid generation of inducible mouse mutants. Nucleic Acids Res (2003) 2.77
Reprogramming of a melanoma genome by nuclear transplantation. Genes Dev (2004) 2.75
Molecular control of pluripotency. Curr Opin Genet Dev (2006) 2.75
Characterization of a highly variable eutherian microRNA gene. RNA (2005) 2.72
Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev (2012) 2.70